ReviewJournal of clinical gastroenterology2014
Current challenges and the management of chronic hepatitis C in mainland China.
Review in Journal of clinical gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review.BMC infectious diseases · 2017Pooled it
- Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.Nature medicine · 2023Trial
- The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study.Virology journal · 2026Article
- Changing Patterns of Mortality in Viral Hepatitis - China, 1987-2021.China CDC weekly · 2023Article
- Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China.World journal of gastroenterology · 2022Article
- Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia.Medicine · 2022Article
- Article
- Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation.BMC medical genomics · 2021Article
- Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data.Virology journal · 2020Article
- Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.International journal of environmental research and public health · 2020Article
- Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study.Canadian journal of gastroenterology & hepatology · 2020Article
- Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.World journal of gastroenterology · 2019Observational
- Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis.BMJ open · 2019Article
- Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C.Journal of clinical and translational hepatology · 2019Article
- Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study.BMJ open · 2019Observational
- Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.World journal of hepatology · 2019Review
- Recombinant streptavidin fusion proteins as signal reporters in rapid test of human hepatitis C virus infection.Journal of clinical laboratory analysis · 2019Article
- The Decade-Long Chinese Methadone Maintenance Therapy Yields Large Population and Economic Benefits for Drug Users in Reducing Harm, HIV and HCV Disease Burden.Frontiers in public health · 2019Article
- [Seroepidemiological investigation of hepatitis C virus in Zhejiang Province: a hospital-based study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite decreasing prevalence, new cases of hepatitis C in China are increasing recently with growing percentage of patients who are with advanced disease, aging, or not eligible for interferon-based treatments. Hepatitis C infection represents a serious public health burden. This review was based on expert's consensus during a medical forum on hepatitis sponsored by the Beijing Wu Jie-Ping Medical Foundation. The literature searches were conducted in PubMed and critical publications in Chinese journals. Data on hepatitis C prevalence, risk factors, viral or host features, and treatment modalities were extracted and reviewed. Recent large-scale surveys reported reducing prevalence of hepatitis C to approximately 0.4% in China, partly because of regulation changes to safer medical practices and illegalizing commercial blood donations. Patient demographics evolved from being dominated by former paid blood donors to include intravenous drug users and others. Although hepatitis C genotype 1 is the most common, other genotypes are emerging in prevalence. The current standard of care is interferon-based without direct acting antivirals. However, many patients failed therapy because of high treatment costs, substantial needs to manage side effects, difficulties with treatment monitoring in the rural areas, and growing populations of elderly and cirrhotic patients. The lack of high efficacy therapies with good safety profile and low disease awareness in China resulted in increasing public burden of advanced hepatitis C disease. Despite significant reduction of hepatitis C prevalence, iatrogenic, nosocomial, and community transmissions are still significant. In addition to promoting disease awareness, interferon-free regimens are needed to reduce the public health burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.